Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · IEX Real-Time Price · USD
1.440
+0.050 (3.60%)
At close: Apr 26, 2024, 4:00 PM
1.420
-0.020 (-1.39%)
After-hours: Apr 26, 2024, 5:11 PM EDT
Nexalin Technology Revenue
In the year 2023, Nexalin Technology had annual revenue of $110.75K, a decrease of -91.62%. Revenue in the quarter ending December 31, 2023 was $20.54K, a -46.55% decrease year-over-year.
Revenue (ttm)
$110.75K
Revenue Growth
-91.62%
P/S Ratio
96.69
Revenue / Employee
$18,458
Employees
6
Market Cap
10.71M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
Dec 31, 2020 | 242.91K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNXL News
- 2 days ago - Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire
- 17 days ago - Nexalin Technology CEO Provides Letter to Shareholders - GlobeNewsWire
- 23 days ago - Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device - GlobeNewsWire
- 25 days ago - Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” - GlobeNewsWire
- 7 weeks ago - Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia - GlobeNewsWire